Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96Q11
UPID:
TRNT1_HUMAN
Alternative names:
Mitochondrial tRNA nucleotidyl transferase, CCA-adding; mt CCA-adding enzyme; mt tRNA CCA-diphosphorylase; mt tRNA CCA-pyrophosphorylase; mt tRNA adenylyltransferase
Alternative UPACC:
Q96Q11; A8K2Z6; B7WP13; C9JKA2; Q8ND57; Q9BS97; Q9Y362
Background:
CCA tRNA nucleotidyltransferase 1, mitochondrial, plays a pivotal role in the synthesis and repair of tRNA molecules by adding the essential 3'-terminal CCA sequence. This enzyme, known by alternative names such as mt CCA-adding enzyme, is crucial for the attachment of amino acids to tRNA, facilitating protein synthesis. Its activity involves using CTP and ATP as substrates to catalyze this addition, which is vital for both tRNA processing and repair.
Therapeutic significance:
The enzyme's dysfunction is linked to diseases such as Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, and Retinitis pigmentosa and erythrocytic microcytosis. These associations underscore the enzyme's therapeutic significance, suggesting that targeting its pathway could lead to novel treatments for these conditions.